2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
Insights
Categories
Topics
Categories
Topics
Implementing a Modular PBA Model As Your Pharmacy Benefits Strategy
Transforming pharmacy benefit strategy into execution for Modular PBA models In today’s prescription drug landscape, where costs continue to soar and patients struggle to…
Read Post
2025 Drugs to Watch: A Helpful Guide for Payers
Stay Ahead of 2025 Drug Trends Managing drug trend and spend continues to be a significant challenge for payers, with specialty drug trends rising…
Read Post
Exploring The 2025 Obesity Drug Pipeline
A Snippet From The 2025 Payer’s Guide to GLP-1 Drugs In recent years, GLP-1 drugs have become increasingly popular for their effectiveness in managing…
Read Post
4 Strategies to Avoid Pitfalls in Your 2025 Project Management Initiatives
In an increasingly demanding and ever-changing healthcare environment, project management missteps can derail even the most promising initiatives. Join our industry experts as they…
Read Post
End-to-End Benefit Validation Tools Ensure Seamless Member Transitions
When a health plan changed PBMs for the first time in 10 years, PSG helped ensure a seamless implementation and transition. 1M testing claims…
Read Post
The Payer’s 2025 Guide to GLP-1 Drugs
Manage Pharmacy Benefits for GLP-1 Drugs GLP-1 drugs are a hot topic not only in pharmacy but in U.S. culture and business. Forecasts have…
Read Post
Pharmacy Benefits Research: Illuminating the Path Forward
Advancing Industry Understanding with Research For over three decades, PSG has been the expert voice in all aspects of managing pharmacy benefits. Our comprehensive…
Read Post
Stelara Biosimilars: Preparing for the Upcoming Market Shift
Leveraging Stelara Biosimilars Could be a Valuable Savings Strategy in 2025 Since its introduction in 2009, Stelara (sold by Janssen) has emerged as a…
Read Post
Pharmaceutical Strategies Group Expands Artemetrx Solutions with Key Addition
DALLAS, TX – December 12, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, announces the appointment of Travis Baughn as Vice President…
Read Post
Kebilidi: A Groundbreaking Gene Therapy Offering Hope for Rare Neurodevelopmental Disorder
The US Food and Drug Administration (FDA) approved the latest multimillion gene therapy. On November 13, 2024, the FDA approved Kebilidi (eladocagene exuparvovec-tneq), a…
Read Post
Pharmacy Benefits Research Unwrapped: Key Trends and Insights from 2024
Independent Pharmacy Benefit Research Helps Move the Industry Forward For over 30 years, PSG has been a trusted independent voice in pharmacy benefits management.
Read Post